NOXOPHARM LIMITED - Announcements

0.00%

12.5¢

Market Cap $36.52M

Healthcare Biotechnology

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel... Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

NOX	HERACLES clinical trial Update 2	PRICE SENSITIVE	11/08/25	304.76KB	Share
NOX	US company demonstrates strong Sofra potential	PRICE SENSITIVE	05/08/25	351.76KB	Share
NOX	June 2025 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	30/07/25	556.89KB	Share
NOX	HERACLES clinical trial - Update 1	PRICE SENSITIVE	28/07/25	298.13KB	Share
NOX	First SOF-SKN dose in HERACLES clinical trial	PRICE SENSITIVE	16/07/25	286.56KB	Share
NOX	Clinical trial recruitment progressing rapidly		25/06/25	276.98KB	Share
NOX	Promising Sofra results from overseas company	PRICE SENSITIVE	11/06/25	320.94KB	Share
NOX	Green light for HERACLES clinical trial	PRICE SENSITIVE	29/05/25	199.26KB	Share
NOX	NYR: Notice of Ceasing to be a Substantial Holder - NOX		21/05/25	231.61KB	Share
NOX	Notice of Change of Interests of Substantial Holder for NYR		20/05/25	212.7KB	Share
NOX	NYR: Corporate Update		20/05/25	217.56KB	Share
NOX	New funds from Nyrada share sales	PRICE SENSITIVE	20/05/25	193.35KB	Share
NOX	SOF-SKN data presented at rheumatology conference		06/05/25	270.37KB	Share
NOX	Noxopharm clinical trial submission		02/05/25	196.4KB	Share
NOX	March 2025 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	30/04/25	446KB	Share
NOX	SOF-SKN successfully passes final pre-trial study		15/04/25	221.76KB	Share
NOX	Noxopharm expands collaboration with Hudson Institute		25/03/25	205.31KB	Share
NOX	Doherty Clinical Trials to host HERACLES trial		12/03/25	191.59KB	Share
NOX	Appendix 4D and FY2025 Half Year Financial Report	PRICE SENSITIVE	25/02/25	1.03MB	Share
NOX	SOF-SKN passes required in vitro safety tests	PRICE SENSITIVE	04/02/25	234.7KB	Share
NOX	December 2024 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	29/01/25	510.1KB	Share
NOX	Notice under s708A(12C)(e) of the Corporations Act 2001		10/01/25	616.66KB	Share
NOX	Notification regarding unquoted securities - NOX		10/01/25	23.46KB	Share
NOX	Notification regarding unquoted securities - NOX		10/01/25	23.33KB	Share
NOX	Convertible Note update		18/12/24	181.31KB	Share
NOX	Change of Director's Interest Notice - BP		16/12/24	4.67KB	Share
NOX	Notification of cessation of securities - NOX		16/12/24	12.65KB	Share
NOX	Contract Research Organisation signed for HERACLES trial		04/12/24	192KB	Share
NOX	Results of Meeting		19/11/24	201.09KB	Share
NOX	Noxopharm 2024 AGM Corporate Presentation		19/11/24	2.45MB	Share
NOX	Noxopharm 2024 AGM Chair Address		19/11/24	206.28KB	Share
NOX	Noxopharm enhances 2024 cash position via R&D rebate		12/11/24	195.66KB	Share
NOX	Notification of cessation of securities - NOX		06/11/24	12.69KB	Share
NOX	Proposed issue of securities - NOX		05/11/24	21.24KB	Share
NOX	Additional convertible note for long-term shareholder	PRICE SENSITIVE	05/11/24	186.85KB	Share
NOX	September 2024 Quarterly Activities report and Appendix 4C	PRICE SENSITIVE	29/10/24	568.55KB	Share
NOX	2024 AGM Addendum to the Notice of Meeting and Proxy		25/10/24	472.71KB	Share
NOX	Minor correction to funding announcement		14/10/24	187.46KB	Share
NOX	AGM Letter of Access, Notice of Meeting and Proxy		14/10/24	1.01MB	Share
NOX	Unlisted Options Upcoming Expiry		11/10/24	191.03KB	Share
NOX	SOF-SKN manufacturer signed for HERACLES clinical trial		10/10/24	212.16KB	Share
NOX	Annual Report to shareholders		30/09/24	3.57MB	Share
NOX	Audited Financial Statements		27/09/24	1.86MB	Share
NOX	Appendix 4G and Corporate Governance Statement		27/09/24	664.74KB	Share
NOX	Proposed issue of securities - NOX		27/09/24	21.31KB	Share
NOX	New funding from sophisticated investors	PRICE SENSITIVE	27/09/24	432.69KB	Share
NOX	Completes SOF-SKN formulation as clinical trial approaches		17/09/24	270.17KB	Share
NOX	Advanced funding secured ahead of R&D rebate	PRICE SENSITIVE	06/09/24	198.62KB	Share
NOX	Significant results from new brain cancer drugs	PRICE SENSITIVE	03/09/24	210.6KB	Share
NOX	Ceasing to be a substantial holder - Goodridge		30/08/24	316.83KB	Share
NOX	Appendix 4E Preliminary Final Report	PRICE SENSITIVE	29/08/24	419.76KB	Share
NOX	Noxopharm Targets Clinical Trial for First-in-Class Drug	PRICE SENSITIVE	19/08/24	224.49KB	Share
NOX	Significant CRO-67 Results in Pancreatic Cancer Studies	PRICE SENSITIVE	14/08/24	229.19KB	Share
NOX	June 2024 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	23/07/24	511.38KB	Share
NOX	Noxopharm joins global Alliance for mRNA Medicines		28/05/24	214.85KB	Share
NOX	Milestone reached as SOF-SKN progresses to next level		14/05/24	208.1KB	Share
NOX	March 2024 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	29/04/24	409.05KB	Share
NOX	Tour de Cure Grant for Brain Cancer Research		04/04/24	217.52KB	Share
NOX	Appendix 4D and Half Year 2024 Financial Report	PRICE SENSITIVE	27/02/24	630.13KB	Share
NOX	Noxopharm extends Hudson Institute strategic partnership		13/02/24	219.18KB	Share
NOX	December 2023 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	22/01/24	453.72KB	Share
NOX	Change of Director's Interest Notice - GM		18/12/23	4.51KB	Share
NOX	Notification of cessation of securities - NOX		18/12/23	21.54KB	Share
NOX	Results of Meeting		16/11/23	277.94KB	Share
NOX	Noxopharm Enhances Cash Position via R&D Rebate	PRICE SENSITIVE	16/11/23	199.04KB	Share
NOX	Noxopharm 2023 AGM Corporate Presentation	PRICE SENSITIVE	16/11/23	1.91MB	Share
NOX	Noxopharm 2023 AGM Chair Address		16/11/23	228.19KB	Share
NOX	Unlisted Options Expiring on 16 December 2023		27/10/23	187.41KB	Share
NOX	mRNA Vaccine Enhancer Shows Inflammation Reduction	PRICE SENSITIVE	18/10/23	386.06KB	Share
NOX	September 2023 Activities Report and Appendix 4C	PRICE SENSITIVE	13/10/23	486.21KB	Share
NOX	Response to ASX Query	PRICE SENSITIVE	09/10/23	373.25KB	Share
NOX	US FDA grants Orphan Drug Designation for CRO-67	PRICE SENSITIVE	04/10/23	202.75KB	Share
NOX	Trading Halt	PRICE SENSITIVE	03/10/23	254.24KB	Share
NOX	Pause in Trading	PRICE SENSITIVE	03/10/23	116.2KB	Share
NOX	Latest CRO-67 data shows success in reducing cancer growth	PRICE SENSITIVE	28/09/23	259.53KB	Share
NOX	2023 AGM Notice of Meeting and Proxy		28/09/23	531.07KB	Share
NOX	2023 AGM Letter to Shareholders and Proxy		28/09/23	508.77KB	Share
NOX	Annual Report to shareholders		27/09/23	9.17MB	Share
NOX	Change of Director's Interest Notice - FB		21/09/23	4.09KB	Share
NOX	Change of Director's Interest Notice - FB		18/09/23	4.11KB	Share
NOX	Appendix 4E and Audited Financial Statements	PRICE SENSITIVE	31/08/23	1.27MB	Share
NOX	Appendix 4G and Corporate Governance Statement		31/08/23	745.79KB	Share
NOX	Notification of cessation of securities - NOX		24/07/23	22.35KB	Share
NOX	June 2023 Activities Report and Appendix 4C	PRICE SENSITIVE	14/07/23	486.75KB	Share
NOX	Upcoming Expiry of Listed Options (ASX Code NOXOA)		05/07/23	1012.17KB	Share
NOX	Unlisted Options expiring on 23 July 2023		05/07/23	184.14KB	Share
NOX	Notification of cessation of securities - NOX		05/07/23	22.2KB	Share
NOX	Change of Director's Interest Notice - FB		03/07/23	4.1KB	Share
NOX	Change of Director's Interest Notice - FB		29/06/23	4.5KB	Share
NOX	Change of Director's Interest Notice - FB		19/06/23	4.76KB	Share
NOX	Change of Director's Interest Notice - BP		19/06/23	5.64KB	Share
NOX	Change of Director's Interest Notice - PM		19/06/23	4.48KB	Share
NOX	Details of Company Address		19/06/23	179KB	Share
NOX	IONIC Trial Abstract Published at ASCO	PRICE SENSITIVE	26/05/23	212.18KB	Share
NOX	Study results show new Sofra drug reduces inflammation	PRICE SENSITIVE	19/05/23	334.35KB	Share
NOX	Innovative Sofra research presented at European event		18/05/23	228.22KB	Share
NOX	Change of Director's Interest Notice - FB		10/05/23	4.76KB	Share
NOX	Upcoming Expiry of Listed Options (ASX Code NOXO)		08/05/23	1012.83KB	Share
NOX	Change of Director's Interest Notice - FB		04/05/23	4.77KB	Share
NOX	March 2023 Quarterly Activities Report and Appendix 4C	PRICE SENSITIVE	24/04/23	480.76KB	Share

NOX HERACLES clinical trial Update 2
11/08/25	PRICE SENSITIVE	304.76KB	Share
NOX US company demonstrates strong Sofra potential
05/08/25	PRICE SENSITIVE	351.76KB	Share
NOX June 2025 Quarterly Activities Report and Appendix 4C
30/07/25	PRICE SENSITIVE	556.89KB	Share
NOX HERACLES clinical trial - Update 1
28/07/25	PRICE SENSITIVE	298.13KB	Share
NOX First SOF-SKN dose in HERACLES clinical trial
16/07/25	PRICE SENSITIVE	286.56KB	Share
NOX Clinical trial recruitment progressing rapidly
25/06/25		276.98KB	Share
NOX Promising Sofra results from overseas company
11/06/25	PRICE SENSITIVE	320.94KB	Share
NOX Green light for HERACLES clinical trial
29/05/25	PRICE SENSITIVE	199.26KB	Share
NOX NYR: Notice of Ceasing to be a Substantial Holder - NOX
21/05/25		231.61KB	Share
NOX Notice of Change of Interests of Substantial Holder for NYR
20/05/25		212.7KB	Share
NOX NYR: Corporate Update
20/05/25		217.56KB	Share
NOX New funds from Nyrada share sales
20/05/25	PRICE SENSITIVE	193.35KB	Share
NOX SOF-SKN data presented at rheumatology conference
06/05/25		270.37KB	Share
NOX Noxopharm clinical trial submission
02/05/25		196.4KB	Share
NOX March 2025 Quarterly Activities Report and Appendix 4C
30/04/25	PRICE SENSITIVE	446KB	Share
NOX SOF-SKN successfully passes final pre-trial study
15/04/25		221.76KB	Share
NOX Noxopharm expands collaboration with Hudson Institute
25/03/25		205.31KB	Share
NOX Doherty Clinical Trials to host HERACLES trial
12/03/25		191.59KB	Share
NOX Appendix 4D and FY2025 Half Year Financial Report
25/02/25	PRICE SENSITIVE	1.03MB	Share
NOX SOF-SKN passes required in vitro safety tests
04/02/25	PRICE SENSITIVE	234.7KB	Share
NOX December 2024 Quarterly Activities Report and Appendix 4C
29/01/25	PRICE SENSITIVE	510.1KB	Share
NOX Notice under s708A(12C)(e) of the Corporations Act 2001
10/01/25		616.66KB	Share
NOX Notification regarding unquoted securities - NOX
10/01/25		23.46KB	Share
NOX Notification regarding unquoted securities - NOX
10/01/25		23.33KB	Share
NOX Convertible Note update
18/12/24		181.31KB	Share
NOX Change of Director's Interest Notice - BP
16/12/24		4.67KB	Share
NOX Notification of cessation of securities - NOX
16/12/24		12.65KB	Share
NOX Contract Research Organisation signed for HERACLES trial
04/12/24		192KB	Share
NOX Results of Meeting
19/11/24		201.09KB	Share
NOX Noxopharm 2024 AGM Corporate Presentation
19/11/24		2.45MB	Share
NOX Noxopharm 2024 AGM Chair Address
19/11/24		206.28KB	Share
NOX Noxopharm enhances 2024 cash position via R&D rebate
12/11/24		195.66KB	Share
NOX Notification of cessation of securities - NOX
06/11/24		12.69KB	Share
NOX Proposed issue of securities - NOX
05/11/24		21.24KB	Share
NOX Additional convertible note for long-term shareholder
05/11/24	PRICE SENSITIVE	186.85KB	Share
NOX September 2024 Quarterly Activities report and Appendix 4C
29/10/24	PRICE SENSITIVE	568.55KB	Share
NOX 2024 AGM Addendum to the Notice of Meeting and Proxy
25/10/24		472.71KB	Share
NOX Minor correction to funding announcement
14/10/24		187.46KB	Share
NOX AGM Letter of Access, Notice of Meeting and Proxy
14/10/24		1.01MB	Share
NOX Unlisted Options Upcoming Expiry
11/10/24		191.03KB	Share
NOX SOF-SKN manufacturer signed for HERACLES clinical trial
10/10/24		212.16KB	Share
NOX Annual Report to shareholders
30/09/24		3.57MB	Share
NOX Audited Financial Statements
27/09/24		1.86MB	Share
NOX Appendix 4G and Corporate Governance Statement
27/09/24		664.74KB	Share
NOX Proposed issue of securities - NOX
27/09/24		21.31KB	Share
NOX New funding from sophisticated investors
27/09/24	PRICE SENSITIVE	432.69KB	Share
NOX Completes SOF-SKN formulation as clinical trial approaches
17/09/24		270.17KB	Share
NOX Advanced funding secured ahead of R&D rebate
06/09/24	PRICE SENSITIVE	198.62KB	Share
NOX Significant results from new brain cancer drugs
03/09/24	PRICE SENSITIVE	210.6KB	Share
NOX Ceasing to be a substantial holder - Goodridge
30/08/24		316.83KB	Share
NOX Appendix 4E Preliminary Final Report
29/08/24	PRICE SENSITIVE	419.76KB	Share
NOX Noxopharm Targets Clinical Trial for First-in-Class Drug
19/08/24	PRICE SENSITIVE	224.49KB	Share
NOX Significant CRO-67 Results in Pancreatic Cancer Studies
14/08/24	PRICE SENSITIVE	229.19KB	Share
NOX June 2024 Quarterly Activities Report and Appendix 4C
23/07/24	PRICE SENSITIVE	511.38KB	Share
NOX Noxopharm joins global Alliance for mRNA Medicines
28/05/24		214.85KB	Share
NOX Milestone reached as SOF-SKN progresses to next level
14/05/24		208.1KB	Share
NOX March 2024 Quarterly Activities Report and Appendix 4C
29/04/24	PRICE SENSITIVE	409.05KB	Share
NOX Tour de Cure Grant for Brain Cancer Research
04/04/24		217.52KB	Share
NOX Appendix 4D and Half Year 2024 Financial Report
27/02/24	PRICE SENSITIVE	630.13KB	Share
NOX Noxopharm extends Hudson Institute strategic partnership
13/02/24		219.18KB	Share
NOX December 2023 Quarterly Activities Report and Appendix 4C
22/01/24	PRICE SENSITIVE	453.72KB	Share
NOX Change of Director's Interest Notice - GM
18/12/23		4.51KB	Share
NOX Notification of cessation of securities - NOX
18/12/23		21.54KB	Share
NOX Results of Meeting
16/11/23		277.94KB	Share
NOX Noxopharm Enhances Cash Position via R&D Rebate
16/11/23	PRICE SENSITIVE	199.04KB	Share
NOX Noxopharm 2023 AGM Corporate Presentation
16/11/23	PRICE SENSITIVE	1.91MB	Share
NOX Noxopharm 2023 AGM Chair Address
16/11/23		228.19KB	Share
NOX Unlisted Options Expiring on 16 December 2023
27/10/23		187.41KB	Share
NOX mRNA Vaccine Enhancer Shows Inflammation Reduction
18/10/23	PRICE SENSITIVE	386.06KB	Share
NOX September 2023 Activities Report and Appendix 4C
13/10/23	PRICE SENSITIVE	486.21KB	Share
NOX Response to ASX Query
09/10/23	PRICE SENSITIVE	373.25KB	Share
NOX US FDA grants Orphan Drug Designation for CRO-67
04/10/23	PRICE SENSITIVE	202.75KB	Share
NOX Trading Halt
03/10/23	PRICE SENSITIVE	254.24KB	Share
NOX Pause in Trading
03/10/23	PRICE SENSITIVE	116.2KB	Share
NOX Latest CRO-67 data shows success in reducing cancer growth
28/09/23	PRICE SENSITIVE	259.53KB	Share
NOX 2023 AGM Notice of Meeting and Proxy
28/09/23		531.07KB	Share
NOX 2023 AGM Letter to Shareholders and Proxy
28/09/23		508.77KB	Share
NOX Annual Report to shareholders
27/09/23		9.17MB	Share
NOX Change of Director's Interest Notice - FB
21/09/23		4.09KB	Share
NOX Change of Director's Interest Notice - FB
18/09/23		4.11KB	Share
NOX Appendix 4E and Audited Financial Statements
31/08/23	PRICE SENSITIVE	1.27MB	Share
NOX Appendix 4G and Corporate Governance Statement
31/08/23		745.79KB	Share
NOX Notification of cessation of securities - NOX
24/07/23		22.35KB	Share
NOX June 2023 Activities Report and Appendix 4C
14/07/23	PRICE SENSITIVE	486.75KB	Share
NOX Upcoming Expiry of Listed Options (ASX Code NOXOA)
05/07/23		1012.17KB	Share
NOX Unlisted Options expiring on 23 July 2023
05/07/23		184.14KB	Share
NOX Notification of cessation of securities - NOX
05/07/23		22.2KB	Share
NOX Change of Director's Interest Notice - FB
03/07/23		4.1KB	Share
NOX Change of Director's Interest Notice - FB
29/06/23		4.5KB	Share
NOX Change of Director's Interest Notice - FB
19/06/23		4.76KB	Share
NOX Change of Director's Interest Notice - BP
19/06/23		5.64KB	Share
NOX Change of Director's Interest Notice - PM
19/06/23		4.48KB	Share
NOX Details of Company Address
19/06/23		179KB	Share
NOX IONIC Trial Abstract Published at ASCO
26/05/23	PRICE SENSITIVE	212.18KB	Share
NOX Study results show new Sofra drug reduces inflammation
19/05/23	PRICE SENSITIVE	334.35KB	Share
NOX Innovative Sofra research presented at European event
18/05/23		228.22KB	Share
NOX Change of Director's Interest Notice - FB
10/05/23		4.76KB	Share
NOX Upcoming Expiry of Listed Options (ASX Code NOXO)
08/05/23		1012.83KB	Share
NOX Change of Director's Interest Notice - FB
04/05/23		4.77KB	Share
NOX March 2023 Quarterly Activities Report and Appendix 4C
24/04/23	PRICE SENSITIVE	480.76KB	Share

REFRESH

1 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 12.5¢		Change 0.000(0.00%)		Mkt cap ! $36.52M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
2	127321	11.5¢

Sellers (Offers)

Price($)	Vol.	No.
12.5¢	63519	2

View Market Depth

No.	Vol.	Price($)
2	127321	0.115
3	155049	0.110
4	116000	0.100
1	150000	0.099
1	100000	0.098

Price($)	Vol.	No.
0.125	63519	2
0.130	350707	6
0.135	346147	5
0.140	100135	4
0.145	153612	4

Last trade - 10.00am 13/08/2025 (20 minute delay)


Last 11.5¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
11.5¢	11.5¢	11.5¢	14744
Last updated 11.03am 13/08/2025 ?

NOX (ASX) Chart

NOXOPHARM LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available